Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci

Journal of the National Cancer Institute

Volumn 90, Issue 9, 1998, Pages 697-703

  O'Connell, Peter ^a   Pekkel, Vladimir ^a   Fuqua, Suzanne A W ^b   Osborne, C Kent ^b   Clark, Gary M ^b   Allred, D Craig ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; BREAST CARCINOMA; BREAST HYPERPLASIA; CARCINOMA IN SITU; CHROMOSOME 11P; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 2P; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRECANCER; TUMOR SUPPRESSOR GENE;

EID: 0032490119     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.9.697     Document Type: Article

References (67)

1. American Cancer Society. Cancer facts and figures - 1997. New York: American Cancer Society, Inc., 1997.
2. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
3. Palli D, Rosselli del Turco M, Simoncini R, Bianchi S. Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer 1991;47:703-6.
4. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer (published erratum appears in JAMA 1992;267:1780]. JAMA 1992;267:941-4.
5. Dupont WD, Pari FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71:1258-65.
6. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-708.
7. Page DL. Cancer risk assessment in benign breast biopsies. Hum Pathol 1986;17:871-4.
8. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994;32:5-12.
9. Radford DM, Fair K, Thompson AM, Ritter JH, Holt M, Steinbrueck T, et al. Allelic loss on chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res 1993;53:2947-9.
10. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996;274:2057-9.
11. Wright DK, Manos MM. Sample preparation from paraffin embedded tissues. In: Innes MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols. San Diego: Academic Press, 1990:153-8.
12. Cooper AP. Illustrations of the diseases of the breast. London: Longman, Rees & Co., 1829.
13. MacCarty WC. The histogenesis of cancer (carcinoma) of the breast and its clinical significance. Surg Gynecol Obstet 1913;17:441-59.
14. Charteris AA. On the changes in the mammary gland preceding carcinoma. J Pathol 1930;33:101-17.
15. Foote FW, Stewart FW. Comparative studies of cancerous versus noncancerous breasts. Ann Surg 1945;121:6-53, 197-222.
16. Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst 1973;50:1111-8.
17. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231-73.
18. Page DL, Dupont WD. Premalignant conditions and markers of elevated risk in the breast and their management. Surg Clin North Am 1990;70:831-51.
19. Davis HH, Simons M, Davis BD. Cystic disease of the breast: relationship to carcinoma. Cancer 1964;17:957-78.
20. Black MM, Barclay TH, Cutler SJ, Hankey BF, Asire AJ. Association of atypical characteristics of benign breast lesions with subsequent risk of breast cancer. Cancer 1972;29:338-43.
21. Kodlin D, Winger EE, Morgenstern NL, Chen U. Chronic mastopathy and breast cancer. A follow-up study. Cancer 1977;39:2603-7.
22. Page DL, Vander Zwaag R, Rogers LW, Williams LT, Walker WE, Hartmann WH. Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst 1978;61:1055-63.
23. Hutchinson WB, Thomas DB, Hamlin WB, Roth GJ, Peterson AV, Williams B. Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst 1980;65:13-20.
24. Page DL, Dupont WD, Rogers LW. Breast cancer risk of lobular-based hyperplasia after biopsy: "ductal" pattern lesions. Cancer Detect Prev 1986;9:441-8.
25. Krieger N, Hiatt RA. Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. Am J Epidemiol 1992;135:619-31.
26. McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D. Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group. Cancer 1992;69:1408-14.
27. Bodian CA, Perzin KH, Lattes R, Hoffmann P, Abernathy TG. Prognostic significance of benign proliferative breast disease. Cancer 1993;71:3896-907.
28. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982;49:751-8.
29. Berardo MD, O'Connell P, Allred DC. Biological characteristics of premalignant and preinvasive breast disease. In: Pasqualini JR, Katzenellenbogen BS, editors. Hormone-dependent cancer. New York, Basel, Hong Kong: Marcel Dekker, Inc., 1996:1-23.
30. Allred DC, Berardo MD, Prosser J, O'Connell P. Biologic and genetic features of in situ breast cancer. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast. Baltimore: Williams & Wilkins, 1997:37-49.
31. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallic BL, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983;305:779-84.
32. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987;235:1394-9.
33. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
34. Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990;62:187-92.
35. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations [published erratum appears in Cell 1990;62: following 608]. Cell 1990;62:193-201.
36. Friedman LS, Ostermeyer EA, Lynch ED, Szabo CI, Anderson LA, Dowd P, et al. The search for BRCA1. Cancer Res 1994;54:6374-82.
37. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region of 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992;2:128-31.
38. Lakhani SR, Slack DN, Hamoudi RA, Collins N, Stratum MR, Sloane JP. Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Lab Invest 1996;74:129-35.
39. Kasami M, Vnencak-Jones CL, Manning S, Dupont WD, Page DL. Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol 1997;150:1925-32.
40. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995;48:611-5.
41. Chuaqui RF, Zhuang Z, Emmert-Buck MR, Liotta LA, Merino MJ. Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 1997;150:297-303.
42. Rosenberg CL, de las Morenas A, Huang K, Cupples LA, Faller DV, Larson PS. Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J Clin Invest 1996;98:1095-100.
43. Noguchi S, Aihara T, Koyama H, Motomura K, Inaji H, Imaoka S. Clonal analysis of benign and malignant human breast tumors by means of polymerase chain reaction. Cancer Lett 1995;90:57-63.
44. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of predominantly intraductal carcinoma and precancerous lesions of the breast by means of polymerase chain reaction. Cancer Res 1994;54:1849-53.
45. Crissman JD, Visscher DW, Kubus J. Image cytophotometric DNA analysis of atypical hyperplasias and intraductal carcinomas of the breast. Arch Pathol Lab Med 1990;114:1249-53.
46. Carpenter R, Gibbs N, Matthews J, Cooke T. Importance of cellular DNA content in pre-malignant breast disease and pre-invasive carcinoma of the female breast. Br J Surg 1987;74:905-6.
47. Petersson C, Johansson B, Pandis N, Gorunova L, Ingrar C, Idvall I, et al. Clonal chromosome aberrations in fibrocystic breast disease associated with increased risk of cancer. Int J Oncol 1994;5:1207-10.
48. Peters G, Fantl V, Smith R, Brookes S, Dickson C. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat 1995;33:125-35.
49. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, Cornelisse C, van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14:6107-15.
50. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A 1991;88:5006-10.
51. Gutmann D, Wood D, Collins F. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A 1991;88:9658-62.
52. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C, Walker RA. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991;6:413-21.
53. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
54. Radford DM, Fair KL, Phillips NJ, Ritter JH, Steinbrueck T, Holt MS, et al. Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 1995;55:3399-405.
55. Munn KE, Walker RA, Varley JM. Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast. Oncogene 1995;10:1653-7.
56. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol 1995;175:195-201.
57. Lakhani SR, Collins N, Sloane JP, Stratton MR. Loss of heterozygosity in lobular carcinoma in situ. J Clin Pathol: Mol Pathol 1995;48:M74-M78.
58. Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 1995;55:3976-81.
59. Fujii H, Marsh C, Cairns P, Sidransky D, Gabrielson E. Genetic divergence in the clonal evolution of breast cancer. Cancer Res 1996;56:1493-7.
60. Fujii H, Szumel R, Marsh C, Zhou W, Gabrielson E. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 1996;56:5260-5.
61. Chappell SA, Walsh T, Walker RA, Shaw JA. Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer 1997;75:1324-9.
62. Nayar R, Zhuang Z, Merino MJ, Silverberg SG. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. Hum Pathol 1997;28:277-82.
63. Man S, Ellis IO, Sibbering M, Blamey RW, Brook JD. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 1996;56:5484-9.
64. Iwase H, Greenman JM, Barnes DM, Bobrow L, Hodgson S, Mathew CG. Loss of heterozygosity of the oestrogen receptor gene in breast cancer. Br J Cancer 1995;71:448-50.
65. Wooster R, Neuhausen SL, Magnion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
66. Zhuang Z, Merino MJ, Chuaqua R, Liotta LA, Emmert-Buck MR. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. Cancer Res 1995;55:467-71.
67. Radford DM, Phillips NJ, Fair KL, Ritter JH, Holt M, Donis-Keller H. Allelic loss and the progression of breast cancer [published erratum appears in Cancer Res 1996;56:935]. Cancer Res 1995;55:5180-3.